BioNTech SE

NasdaqGS:BNTX Stock Report

Market Cap: US$22.9b

BioNTech Management

Management criteria checks 2/4

BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 17.92 years. total yearly compensation is €264.88M, comprised of 0.3% salary and 99.7% bonuses, including company stock and options. directly owns 17.54% of the company’s shares, worth $4.01B. The average tenure of the management team and the board of directors is 2.9 years and 5.7 years respectively.

Key information

Ugur Sahin

Chief executive officer

€264.9m

Total compensation

CEO salary percentage0.26%
CEO tenure17.9yrs
CEO ownership17.5%
Management average tenure2.9yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 09

The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 08
The BioNTech SE (NASDAQ:BNTX) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

Jul 01
Does BioNTech (NASDAQ:BNTX) Have A Healthy Balance Sheet?

BioNTech's Pivot Into Oncology Still Makes It A Compelling Investment

Mar 17

Analysts Just Slashed Their BioNTech SE (NASDAQ:BNTX) EPS Numbers

Mar 16
Analysts Just Slashed Their BioNTech SE (NASDAQ:BNTX) EPS Numbers
User avatar

Advancing Oncology Pipeline May Drive Future Growth Amid Near-Term Earnings Pressure

Promising oncology assets, improved R&D efficiencies, and strategic partnerships drive potential long-term revenue growth and shareholder value for BioNTech.

BioNTech SE: Lackluster Financials And Uncertainties In Product Pipeline-Hold

Jan 23

BioNTech SE (NASDAQ:BNTX) Investors Are Less Pessimistic Than Expected

Jan 15
BioNTech SE (NASDAQ:BNTX) Investors Are Less Pessimistic Than Expected

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech's Oncology Gamble: High Stakes, Big Potential

Oct 21

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Aug 20

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

CEO Compensation Analysis

How has Ugur Sahin's remuneration changed compared to BioNTech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-€572m

Jun 30 2025n/an/a

-€345m

Mar 31 2025n/an/a

-€766m

Dec 31 2024€265m€700k

-€665m

Sep 30 2024n/an/a

-€467m

Jun 30 2024n/an/a

-€504m

Mar 31 2024n/an/a

€113m

Dec 31 2023€1m€700k

€930m

Sep 30 2023n/an/a

€3b

Jun 30 2023n/an/a

€4b

Mar 31 2023n/an/a

€6b

Dec 31 2022€6m€360k

€9b

Sep 30 2022n/an/a

€10b

Jun 30 2022n/an/a

€12b

Mar 31 2022n/an/a

€13b

Dec 31 2021€12m€360k

€10b

Sep 30 2021n/an/a

€7b

Jun 30 2021n/an/a

€4b

Mar 31 2021n/an/a

€1b

Dec 31 2020€17m€360k

€15m

Sep 30 2020n/an/a

-€410m

Jun 30 2020n/an/a

-€230m

Mar 31 2020n/an/a

-€192m

Dec 31 2019€7m€311k

-€179m

Sep 30 2019n/an/a

-€122m

Jun 30 2019n/an/a

-€116m

Mar 31 2019n/an/a

-€77m

Dec 31 2018€653k€210k

-€48m

Compensation vs Market: Ugur's total compensation ($USD311.99M) is above average for companies of similar size in the US market ($USD13.39M).

Compensation vs Earnings: Ugur's compensation has increased whilst the company is unprofitable.

CEO

Ugur Sahin (60 yo)

17.9yrs
Tenure
€264,882,000
Compensation

Dr. Ugur Sahin, MD, is Co-Founder & CEO of BioNTech US Inc. Dr. Sahin has M.D. from Universität zu Köln in 1990. He is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its...

Leadership Team

NamePositionTenureCompensationOwnership
Ugur Sahin
Co-Founder17.9yrs€264.88m17.54%
$ 4.0b
Ozlem Tureci
Co-Founder7.9yrs€2.53m0.33%
$ 74.8m
Sierk Poetting
MD, COO & Member of Management Board11.9yrs€2.57m0.32%
$ 72.9m
James Timothy Ryan
Chief Legal & Business Officer and Member of the Management Board2.3yrs€881.00k0.00033%
$ 75.4k
Annemarie Hanekamp
Chief Commercial Officer & Member of Management Boardno data€1.73mno data
Ramon Zapata-Gomez
CFO & Member of Management Boardless than a yearno datano data
Lisa Birringer
Senior Vice President of Global Financial Reporting & Accounting1.2yrsno datano data
Douglas Maffei
Vice President of Strategy & Investor Relationsno datano datano data
Jasmina Alatovic
Vice President Corporate Communicationsno datano datano data
Beate Berns
Senior Vice President of Global Human Resources2.9yrsno datano data
Oliver Henning
Senior Vice President of Operationsno datano datano data
Sebastian Kreiter
Senior Vice President of Immunotherapy & Preclinical Researchno datano datano data
2.9yrs
Average Tenure
51.5yo
Average Age

Experienced Management: BNTX's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rudolf Staudigl
Supervisory Board Member3.5yrs€114.00k0.00017%
$ 38.8k
Ulrich Wandschneider
Independent Deputy Chairman Supervisory Board7.9yrs€157.00k0.00062%
$ 141.7k
Michael Motschmann
Independent Supervisory Board Member17.9yrs€100.00kno data
Helmut Jeggle
Independent Supervisory Board Chairman17.9yrs€288.00k0.14%
$ 31.6m
Nicola Blackwood
Member of Supervisory Board2.6yrs€100.00kno data
Anja Morawietz
Supervisory Board Member3.5yrs€130.00k0.00010%
$ 22.9k
5.7yrs
Average Tenure
59.5yo
Average Age

Experienced Board: BNTX's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/24 04:30
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harry GillisBerenberg
Zhiqiang ShuBerenberg
Evan SeigermanBMO Capital Markets Equity Research